Posted by Michael Wonder on 10 Jan 2018
NICE backs wider use of MSD’s Simponi
10 January 2018 - Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
The guidelines endorse the drug’s use in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.
The National Institute for Health and Care Excellence already backs use of Humira (adalimumab), etanercept and certolizumab pegol for treating the condition.
